Company Takeda Pharmaceutical Company Limited BOERSE MUENCHEN
Equities
TKDA
US8740602052
Pharmaceuticals
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
12.1 EUR | 0.00% |
|
+1.68% | -6.20% |
06-25 | US CDC alerts healthcare providers of increase in dengue cases | RE |
06-25 | Takeda's Cancer Drug Gets European Commission Approval | MT |
Business Summary
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sales per Business
JPY in Million | 2023 | Weight | 2024 | Weight | Delta |
---|---|---|---|---|---|
Gastroenterology
28.5
%
| 1,094,541 | 27.2 % | 1,216,207 | 28.5 % | +11.12% |
Plasma-derivatives Therapies Immunology
19.2
%
| 678,443 | 16.8 % | 818,570 | 19.2 % | +20.65% |
Neuroscience
14.7
%
| 637,711 | 15.8 % | 627,014 | 14.7 % | -1.68% |
Rare Genetics and Other
10.9
%
| 418,724 | 10.4 % | 465,403 | 10.9 % | +11.15% |
Oncology
10.8
%
| 438,742 | 10.9 % | 462,362 | 10.8 % | +5.38% |
Other
8.7
%
| 454,598 | 11.3 % | 368,908 | 8.7 % | -18.85% |
Rare Hematology
7.2
%
| 304,718 | 7.6 % | 305,297 | 7.2 % | +0.19% |
Sales per region
JPY in Million | 2023 | Weight | 2024 | Weight | Delta |
---|---|---|---|---|---|
United States
51.5
%
| 2,103,772 | 52.2 % | 2,195,711 | 51.5 % | +4.37% |
Europe and Canada
22.7
%
| 842,668 | 20.9 % | 966,835 | 22.7 % | +14.73% |
Japan
10.6
%
| 512,043 | 12.7 % | 451,391 | 10.6 % | -11.85% |
Asia
6.1
%
| 225,007 | 5.6 % | 261,218 | 6.1 % | +16.09% |
Latin America
4.6
%
| 160,375 | 4.0 % | 198,100 | 4.6 % | +23.52% |
Other
2.8
%
| 95,182 | 2.4 % | 117,911 | 2.8 % | +23.88% |
Russia / Commonwealth of Independent States
1.7
%
| 88,431 | 2.2 % | 72,594 | 1.7 % | -17.91% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
Chief Tech/Sci/R&D Officer | 69 | 15-03-31 | |
Andrew Plump
CTO | Chief Tech/Sci/R&D Officer | 58 | 15-01-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Norimasa Takeda
CMP | Compliance Officer | - | - |
Haruhiko Hirate
IRO | Public Communications Contact | - | - |
Takashi Okubo
IRO | Public Communications Contact | - | - |
Investor Relations Contact | - | 11-05-31 | |
Marcello Agosti
PRN | Corporate Officer/Principal | 53 | 18-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
John Maraganore
BRD | Director/Board Member | 60 | 22-05-31 |
Emiko Higashi
BRD | Director/Board Member | 64 | 16-05-31 |
Michel Orsinger
BRD | Director/Board Member | 66 | 16-05-31 |
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Andrew Plump
CTO | Chief Tech/Sci/R&D Officer | 58 | 15-01-31 |
Kimberly Reed
BRD | Director/Board Member | 53 | 22-05-31 |
Miki Tsusaka
BRD | Director/Board Member | 61 | 23-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,582,418,725 | 1,568,501,201 ( 99.12 %) | 13,405,261 ( 0.8471 %) | 99.12 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
7,514,200 | 0.47% | 199,540,257 $ | |
HILLEVAX, INC. 13.52% | 6,724,000 | 13.52% | 81,629,360 $ |
DENALI THERAPEUTICS INC. 2.96% | 4,214,559 | 2.96% | 78,222,215 $ |
2,204,000 | 7.21% | 33,085,588 $ | |
OVID THERAPEUTICS INC. 12.38% | 8,781,996 | 12.38% | 26,872,908 $ |
2,790,480 | 4.77% | 26,286,322 $ | |
WAVE LIFE SCIENCES LTD. 0.90% | 1,096,892 | 0.90% | 6,778,793 $ |
NOILE-IMMUNE BIOTECH INC. 18.76% | 8,119,800 | 18.76% | 6,768,828 $ |
Company contact information
Takeda Pharmaceutical Co., Ltd.
4-1-1 Dosho-machi Chuo-Ku
540-8645, Osaka
+81 3 3278 2111
http://www.takeda.co.jp![address Takeda Pharmaceutical Company Limited(TKDA)](https://cdn.zonebourse.com/static/address/111965836.png)
Group companies
Name | Category and Sector |
---|---|
Shire Biotech India Pvt Ltd.
| |
Takeda Austria GmbH
![]() Takeda Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Austria GmbH engages in research and development of pharmaceutical products. The company is based in Linz, Austria. Kirsten Detrick has been the CEO of the Austrian company since 2016. |
Miscellaneous Commercial Services
|
Takeda Belgium NV
![]() Takeda Belgium NV Medical DistributorsDistribution Services Founded in 1835, Takeda Belgium NV is a subsidiary of Takeda Pharmaceutical Co., Ltd. The company is based in Zaventem, Belgium and focuses on providing better healthcare solutions for their patients. Takeda Belgium's mission is centered around the question of how they can do more for their patients. |
Medical Distributors
|
Takeda Pharmaceuticals U.S.A., Inc.
![]() Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. |
Pharmaceuticals: Major
|
Takeda GmbH
![]() Takeda GmbH Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda GmbH is a German pharmaceutical company that manufactures pharmaceutical products. The company is based in Konstanz, Germany. The CEOs are Wolfgang Eck, Uwe Hoffmeister, Roland Kurney. The company was founded in 1873. |
Pharmaceuticals: Major
|
Shire Ireland Finance Trading Ltd.
| |
Shire Biotech UK Holdings Ltd.
![]() Shire Biotech UK Holdings Ltd. Financial ConglomeratesFinance Part of Takeda Pharmaceutical Co., Ltd., Shire Biotech UK Holdings Ltd. is an investment holding company. Shire Biotech UK Holdings Ltd. is based in London, UK. Founded in 2017, Shire Biotech UK Holdings functions as an investment holding company. |
Financial Conglomerates
|
Takeda Manufacturing Austria AG
![]() Takeda Manufacturing Austria AG Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda Manufacturing Austria AG manufactures and supplies vital medicines and medical devices. The company is based in Vienna, Austria. |
Pharmaceuticals: Major
|
Takeda A/S
![]() Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. |
Financial Conglomerates
|
Sector
Sales per Business
Sales per region
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.61% | 811B | |
+43.76% | 640B | |
-6.33% | 353B | |
+20.62% | 333B | |
+10.44% | 302B | |
+18.11% | 246B | |
+2.66% | 225B | |
+12.90% | 218B | |
+8.61% | 168B |
- Stock Market
- Equities
- 4502 Stock
- TKDA Stock
- Company Takeda Pharmaceutical Company Limited